SCHEMBL20579818

SCHEMBL20579818

CC(C)(C)OC(=O)c1c(-c2cccc(Br)c2)nc2ccccn12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ ALDH1A1 P00352 4/20 0.47
▸ KCNK3 O14649 1/20 0.44
▸ KCNK9 Q9NPC2 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ PKM P14618 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ RAB9A P51151 4/20 0.43
▸ NPC1 O15118 3/20 0.43
▸ MAPT P10636 2/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ KMT2A Q03164 1/20 0.42
▸ DAPK3 O43293 1/20 0.42
▸ JAK2 O60674 1/20 0.42
▸ PRKD3 O94806 1/20 0.42
▸ MAP4K4 O95819 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20579781 0.87 CYP1A2 (0.69) CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1
SCHEMBL1786995 0.86 KMT2A (0.55) CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1
SCHEMBL1788950 0.79 SMN1; SMN2 (0.49) CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1
SCHEMBL12651708 0.78 SMN1; SMN2 (0.48) CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1
SCHEMBL20579752 0.75 GABRD (0.52) CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1
SCHEMBL12651709 0.74 ALDH1A1 (0.46) CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1
SCHEMBL23509651 0.72 AKT2 (0.51) SMN1; SMN2ALDH1A1KDM4ERAB9ANPC1
SCHEMBL24122954 0.72 NPC1 (0.48) SMN1; SMN2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL14710313 0.71 CYP1A2 (0.82) CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1
SCHEMBL13312213 0.71 CYP1A2 (0.67) CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10323033-B2 Imidazo[1,2-A]pyridine-3-carboxylate derivative and preparation method thereof KNU-INDUSTRY COOPERATION FOUNDATION (KR) 2019-06-18 — — US disclosed
US-20180354948-A1 IMIDAZO[1,2-A]PYRIDINE-3-CARBOXYLATE DERIVATIVE AND PREPARATION METHOD THEREOF KNU-INDUSTRY COOPERATION FOUNDATION (KR) 2018-12-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180354948-A1 IMIDAZO[1,2-A]PYRIDINE-3-CARBOXYLATE DERIVATIVE AND PREPARATION METHOD THEREOF AZI2, AOC3, AOC2 CYP1A2 10/4885CYP2C9 219/4885CYP2C19 140/4885
US-10323033-B2 Imidazo[1,2-A]pyridine-3-carboxylate derivative and preparation method thereof AZI2, AOC3, AOC2 CYP1A2 10/4885CYP2C9 219/4885CYP2C19 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback